Unique opportunity to acquire an established Louisiana CLIA clinical laboratory with active Medicare, pending Medicaid enrollment, approximately $150,000 in laboratory equipment, and a significant potential statewide hospital-system contract.
Purchase Price & Seller Financing
The $700,000 purchase price is structured as follows:
- $300,000 at closing for the existing laboratory platform, licenses/credentials, setup, and equipment.
- $400,000 seller-financed note attributable to the hospital-system account opportunity.
The $400,000 seller note may be paid either:
- $400,000 balloon payment within six (6) months, or
- Within twelve (12) months with 6% annual interest.
This structure allows a qualified laboratory operator to acquire control of the existing laboratory platform for $300,000 at closing while deferring $400,000 of the purchase consideration.
Existing Laboratory
- Active CLIA clinical laboratory
- Active Medicare
- Medicaid enrollment pending
- Approximately $150,000 equipment value
- Established Louisiana laboratory infrastructure
- Positioned to service institutional and hospital accounts
Major 11-Hospital System Opportunity
A Louisiana hospital system comprising 11 hospitals is seeking a single laboratory provider for referred testing beyond its routine in-house capabilities.
Current hospital operations indicate substantial demand for: Microbiology, Molecular testing, Esoteric chemistry, Anatomic pathology, other reference laboratory testing.
Based on available RFP data, the hospitals' Top-20 referred tests alone represent approximately 96,000 tests annually.
More complete utilization data available for one facility indicates that its Top-20 tests represent only approximately two-thirds of actual send-out volume. Extrapolating from the available information suggests potential system-wide referral volume of approximately 130,000-150,000 tests annually.
Strategic Contract Potential
The hospital system is seeking a single vendor for both clinical laboratory and anatomic pathology services.
The opportunity also encompasses:
- Medical directorships at six facilities
- Statewide courier services
- MedHost interfaces across all 11 hospitals
- Potential multi-year relationship
- Significant recurring reference-testing volume
Based on currently available utilization information and estimated reimbursement, the existing send-out volume could potentially represent approximately $2.0–$2.9 million in annual revenue, with estimated operating profit of approximately $300,000–$700,000, depending on actual test mix, payer mix, reimbursement, and operating costs.
Additional Molecular Growth Potential
Existing utilization indicates substantial potential for expansion into higher-margin molecular testing.
Documented testing demand includes approximately:
- 14,000–16,000 blood cultures annually
- 16,000–18,000 urine cultures annually
- Existing GC/Chlamydia/Trich PCR testing
- Significant respiratory and Strep-A volume
- Behavioral health, pain-management, MAT, and drug-confirmation populations potentially relevant to medically appropriate PGx testing
For an experienced molecular laboratory operator, infectious-disease molecular testing and appropriately indicated PGx testing could represent significant additional upside, subject to medical necessity, payer coverage, utilization management, and reimbursement requirements.
Ideal Buyer
This opportunity is particularly suitable for an experienced laboratory operator seeking an established Louisiana laboratory platform with the infrastructure and capabilities to pursue a substantial institutional relationship.
The opportunity should not be evaluated solely on the laboratory's existing operations. A significant component of its potential value is the 11-hospital system opportunity and associated future testing volume.
Important: The hospital-system business is an opportunity and is not represented as guaranteed revenue. Test volumes, revenue, and profitability figures are estimates based on currently available information and are subject to the RFP process, contract award, actual utilization, payer mix, reimbursement, medical necessity, and Buyer's independent due diligence.
Detailed supporting information, utilization data, and available RFP materials will be provided to qualified buyers following NDA and financial qualification.
For this and similar laboratory acquisition opportunities, please contact Sasa Milosevic, specialized laboratory business broker with Manhattan Biz.
